Theriva BiologicsFRA:SFY0 24 PB Ratio is 8.34 as of Jul. 11, 2026, which is 983% above its 10-year median of 0.77. GuruFocus rates FRA:SFY0 with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, Theriva Biologics ranks better than 90.46% on this metric.
Theriva Biologics Inc stock PB Ratio (=0.7) is close to 1-year low of 0.68.
The historical rank and industry rank for Theriva Biologics's PB Ratio or its related term are showing as below:
FRA:SFY0'
s PB Ratio Range Over the Past 10 Years
Min: 0.68 Med: 0.77 Max: 1.16
Current: 0.7
During the past 13 years, Theriva Biologics's highest PB Ratio was 1.16. The lowest was 0.68. And the median was 0.77.
FRA:SFY0's PB Ratio is ranked better than 90.46% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs FRA:SFY0: 0.70
During the past 12 months, Theriva Biologics's average Book Value Per Share Growth Rate was -94.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -82.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Theriva Biologics was 22.20% per year. The lowest was -82.90% per year. And the median was -19.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Theriva Biologics PB Ratio Related Terms
Theriva Biologics PB Ratio Historical Data
* Premium members only.
The historical data trend for Theriva Biologics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theriva Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theriva Biologics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theriva Biologics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Theriva Biologics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Theriva Biologics (FRA:SFY0) has a PB Ratio of 8.34 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Theriva Biologics and its competitors. This is 983% above median its historical median of 0.77. Over the past decade, Theriva Biologics' PB Ratio has ranged from 0.68 to 1.16. According to the industry distribution chart, Theriva Biologics ranks #117 out of 1227 companies in the Biotechnology industry, placing it in the top 9.5%.
Is Theriva Biologics' PB Ratio too high?
Theriva Biologics' current PB Ratio of 8.34 is 983% above median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 1.16. The Biotechnology industry median PB Ratio is 2.95. Theriva Biologics' value of 8.34 is 182.7% above this industry median. Based on the distribution chart, Theriva Biologics ranks #117 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Theriva Biologics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' PB Ratio compare to OSRH and PBM?
According to the Biotechnology industry distribution chart, Theriva Biologics ranks #117 out of 1227 companies for PB Ratio. This places Theriva Biologics in the top 10% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.95. Theriva Biologics' value of 8.34 is 182.7% above this benchmark. Historically, Theriva Biologics' own PB Ratio has ranged from 0.68 to 1.16 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 2.95, Theriva Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theriva Biologics's current PB Ratio of 8.34 is 182.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Theriva Biologics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theriva Biologics's current PB Ratio is 8.34, which is 983% above median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (FRA:SFY0) has a current PB Ratio of 8.34. The current PB Ratio is 8.34, which is 983% above median its 10-year median of 0.77 and 182.7% above the Biotechnology industry median of 2.95. Theriva Biologics' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Theriva Biologics (FRA:SFY0), the current PB Ratio is 8.34 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
24GF Score
Get the complete analysis for FRA:SFY0
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SFY0 has been successfully added to your 
